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Abstract
Background: More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom,
lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory
conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The
tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new,
easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various
respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases.
Objective: The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to
measure the exhaled breath condensate hydrogen peroxide (EBC H2O2) and compare these results with those of healthy controls
and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity,
breath temperature, breath flow dynamics, and end tidal carbon dioxide.
Methods: We will perform a single-visit, cross-sectional observational study of EBC H2O2 levels, as measured by Inflammacheck,
in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma,
chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung
disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record
their breath sample.
Results: The results from this study will be available in 2022, in anticipation of COVID-19–related delays.
Conclusions: This study will investigate the EBC H2O2, as well as other exhaled breath parameters, for use as a future diagnostic
tool.
(JMIR Res Protoc 2021;10(7):e23831) doi: 10.2196/23831
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Introduction
Respiratory Diseases
Globally, respiratory disease is a leading cause of morbidity
and mortality, with over 7% of the world’s population living
with a chronic respiratory disease [1], including a significant
burden on children. Respiratory diseases account for more than
10% of all disability-adjusted life years worldwide [2].
Diagnosing respiratory conditions at an earlier stage affords
patients the opportunity to receive appropriate treatment, along
with reducing symptoms and improving quality of life and
reducing the impact of frequent visits to health care services
due to misdiagnosis or exacerbations. A rapid point-of-care test
may be more useful in low-resource settings.
Within the United Kingdom, approximately 1 in 5 people have
ever developed asthma, chronic obstructive pulmonary disease
(COPD), or other long-term respiratory illness [3]. In addition,
lung diseases are responsible for more than 700,000 hospital
admissions and over 6 million inpatient bed days each year [3].
It is estimated that each week, 10,000 people are given a new
diagnosis of lung disease, but there are thousands of more people
living with the symptoms of lung conditions without a diagnosis.
Table 1 presents the respiratory conditions that are under
investigation in this study. As the table shows, there is no one
gold standard diagnostic investigation to support the diagnosis
of these different conditions. As a consequence, patients can
undergo multiple investigations, leading to a delay in diagnosis
and a prolonged period of struggling with untreated symptoms.
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Table 1. Disease group summaries and diagnostic investigations.
Diagnostic investigationsBackground (key facts)Respiratory disease
Spirometry, chest x-ray, and CTc scanIn the United Kingdom, there are an estimated 3 million people affected by COPD, with
a third of those having a diagnosis and two-thirds who remain undiagnosed [4]. COPD
is common and treatable but is a leading cause of morbidity and mortality worldwide,
and its prevalence is likely to increase in the next decade [5]. COPD is responsible for
a significant financial burden on the NHSb, with the total annual cost of COPD reaching
£982 million (US $1.3 billion), as well as the personal burden, causing almost 22 million
lost working days per year [6].
COPDa
Peak expiratory flow, spirometry,
bronchial provocation, exhaled nitric
oxide, and eosinophilic markers
Asthma affects over 5.4 million people in the United Kingdom, with 200,000 experienc-
ing severe disease with frequent exacerbations [7]. The National Review of Asthma
Deaths in 2014 found that there were 900 deaths due to asthma, highlighting that more
needs to be done regarding the diagnosis and management of this disease [8]. Treating
asthma costs the NHS over £1 billion (US $1.42 billion) per year, and it is a burden for
the person living with asthma, with significant psychological and physical morbidity
[9,10]. Delays in diagnosing asthma and achieving good disease control cause an increase
in emergency health care use and inappropriate treatment.
Asthma
Chest x-ray, CT scan, and sputum
microbiology
The prevalence of bronchiectasis in the United Kingdom is rising, and it is estimated
that the number of people living with this disease exceeds 300,000 [11,12]. People with
bronchiectasis experience symptoms of excessive sputum production and recurrent
respiratory infections, sometimes requiring hospital admission.
Bronchiectasis
CT scan or lung biopsyILDs are a group of diffuse parenchymal lung disorders associated with substantial
morbidity and mortality. ILD can be difficult to diagnose and often requires collaborative
expertise from multiple specialties to reach a consensus. As a consequence, ILD is often
diagnosed late in the course of the disease, impacting patients’ quality of life, and can
even limit access to novel treatments [13,14]. For example, idiopathic pulmonary fibrosis,
one of the more common ILDs, is a chronic, progressive disease with a median survival
of only 3 years from the time of diagnosis [15]. As such, developing a test that could
confirm ILD at an earlier stage is urgently required.
ILDd
CT scan and lung biopsyLung cancer is a leading cause of global cancer death [16]. Even with recent advances
in treatment options, approximately 86% of lung cancer patients die within 5 years of
diagnosis. However, with early detection and treatment, 5-year survival rates improve
to 70% in patients with stage 1 disease [17]. Consequently, new, accurate diagnostic
tests that can detect lung cancer at the earliest stage possible are urgently needed.
Lung cancer
Chest x-ray and CT scanPneumonia is the most common cause of respiratory hospital admissions. It is the in-
flammation of one or both lungs, normally caused by an infection. It is estimated that
approximately 220,000 people receive a diagnosis of pneumonia each year [3]. Pneumo-
nia is responsible for over 5% of all deaths and over 25% of all respiratory deaths [3].
It can be difficult to diagnose, and diagnosis can depend upon the quality of the chest
x-ray or the ability of the person to mount an immune response.
Pneumonia
Clinical assessmentBPD is a very common, potentially debilitating, and easily treatable condition. Unfortu-
nately, it is rarely considered as a common cause of breathlessness, and besides the
Nijmegen questionnaire, there is no quick and easy way of diagnosis [18].
BPDe
aCOPD: chronic obstructive pulmonary disease.
bNHS: National Health Service.
cCT: computed tomography.
dILD: interstitial lung disease.
eBPD: breathing pattern disorder.
Airway and Lung Inflammation
A common feature of most of these lung conditions is airway
inflammation. The current breathing devices to measure the
levels of inflammation focus on eosinophilic rather than
neutrophilic inflammation, which is the predominant phenotype
in COPD, bronchiectasis, steroid-resistant asthma, and
pneumonia. Prolonged exposure to toxic irritants has been
implicated in airway inflammation in lung cancer [19].
Interstitial lung disease (ILD) is an umbrella term for lung
diseases characterized by fibrosis, which can occur as a result
of chronic inflammation, remodeling, and repair [20].
Airway inflammation leads to an imbalance between the
production of reactive oxygen species (ROS) and the ability of
the body to counteract their harmful effects through
neutralization by antioxidants. This results in oxidative stress
[21,22]. Increased expression of ROS by activated inflammatory
cells, including neutrophils, macrophages, and eosinophils, can
lead to further generation of inflammatory mediators, causing
damage to epithelial cells and increased bronchial
hyperreactivity. ROS are metabolized in cells to produce highly
reactive oxidants such as hydrogen peroxide (H2O2), which is
fat soluble and can move across cell membranes. As H2O2 is
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volatile and readily equilibrates with air, its presence is detected
in exhaled breath condensate (EBC). Therefore, measurement
of exhaled breath condensate hydrogen peroxide (EBC H2O2)
provides a quantitative measure of oxidative stress and airway
or lung inflammation [23,24].
Breathing pattern disorder (BPD) is a noninflammatory
condition but is a common comorbidity with other respiratory
disorders. Preliminary data have shown that breath flow
dynamics in a person with BPD is unique (D. Neville,
unpublished data, 2018); therefore, by studying those with BPD
only, we may be able to identify specific features and use the
device to assess when dual pathology is present.
Inflammacheck
In contrast to the current measures of airway inflammation, the
collection of EBC H2O2 is performed during tidal breathing,
making it noninvasive and easy to perform. It can be repeated
quickly and is well tolerated even in patients with severe airway
disease. It is widely appreciated that EBC H2O2 measurement
has the potential to improve clinical practice by safely providing
vital information on aspects of disease that are currently
inaccessible [25]. To date, measurement of H2O2 in EBC
requires complex, multistep processing of the collected breath
samples to produce a result, and consequently, it has largely
been used as a research tool.
Exhalation Technology Ltd developed a table-top device for
point-of-care H2O2 measurement in exhaled breath—the
Inflammacheck device. Previous studies including EXHALE
1A (Exhaled Hydrogen Peroxide as a Marker of Lung Disease
Study 1–Airways; A. Chauhan, unpublished data, 2019) and
EXHALE 1B (Exhaled Hydrogen Peroxide as a Marker of Lung
Disease Study 1–Breathlessness; [26]) have shown that it
accurately measures the level of H2O2 in EBC and that levels
of H2O2 are significantly higher in patients with asthma, COPD,
ILD, and lung cancer than in healthy controls. The EXHALE
1V (Exhaled Hydrogen Peroxide as a Marker of Lung Disease
Study 1–Validation) COPD validation study was terminated
early as significant changes were made in the sensor processing
and device housing, which made the results unreliable.
Participant feedback from these studies helped refine the device
further, and now, Exhalation Technology Ltd has produced a
handheld device (Figure 1), which can accurately and reliably
measure the H2O2 level in a single test. This new device can
also measure additional parameters, including breath humidity,
breath temperature, breath flow dynamics, and carbon dioxide
(CO2) waveform. Previous studies have demonstrated significant
differences in H2O2 levels between healthy controls and some
respiratory diseases including asthma, COPD, and ILD. We
now want to expand upon these results to determine whether
these differences are seen across a wider spectrum of respiratory
diseases and whether the additional parameters measured by
the Inflammacheck device (Exhalation Technology Ltd) also
reflect differences between conditions. This could potentially
provide a unique test that measures common biological and
physiological parameters in a point-of-care device to aid earlier
diagnosis and support personalized management plans. This
simple, noninvasive technique may also make repeat sampling
and longitudinal monitoring of global airway inflammation a
realistic possibility. The Inflammacheck device is currently
Conformité Européenne marked for adults only, which is the
subject of this protocol.
Figure 1. The Inflammacheck device.
Objectives
Primary Objective
The primary objective is to measure and compare the levels of
H2O2 in EBC in patients with a range of commonly occurring
respiratory conditions and compare these results with those of
healthy controls, and with each other.
Secondary Objectives
The secondary objectives are as follows:
• To assess whether the device can measure EBC H2O2
consistently (pilot phase only) and ensure that there are no
safety issues or participant issues when using the device
• To determine whether EBC H2O2, as measured by
Inflammacheck, can differentiate between patients with
asthma, COPD, lung cancer, ILD, BPD, bronchiectasis, and
pneumonia and healthy controls
• To measure and compare the levels of the following
parameters using Inflammacheck in patients with a range
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• Exhaled CO2 waveform
• Breath flow dynamics
• To determine whether H2O2, breath humidity, breath
temperature, exhaled CO2 waveform, and breath flow
dynamics, as measured by Inflammacheck, can either alone
or in combination differentiate patients with asthma, COPD,
lung cancer, ILD, BPD, bronchiectasis, and pneumonia
from each other and from healthy controls
• To assess the experience of a small group of participants
and health care professionals in using the Inflammacheck
device using a questionnaire methodology
Methods
Overview
This is a cross-sectional observational study of EBC H2O2 levels,
as measured by Inflammacheck, in people with asthma, COPD,
bronchiectasis, ILD, lung cancer, pneumonia, and BPD and in
healthy volunteers. The participants were screened for the
absence of COVID-19 symptoms before testing.
Outcome Measures
Respiratory Outcomes
Respiratory outcomes will include the following:
• EBC H2O2 measured by Inflammacheck
• Breath humidity
• Breath temperature
• Exhaled CO2 waveform
• Breath flow dynamics
• Forced expiratory volume in 1 second (FEV1), forced vital
capacity (FVC), and expiratory ratio as appropriate.
Experience Outcomes (by Questionnaire)
Experience outcomes will include the following:
• Rating of ease of use of the test
• Rating of whether the test is acceptable to the participant
• The participant’s perception of the device
• The health care professional’s experience of the device
Eligibility Criteria
Study Participants
Participants with the abovementioned respiratory conditions
and healthy volunteers will be recruited. There are some
overarching inclusion and exclusion criteria, along with some
specific respiratory condition criteria to ensure that each disease
is well defined.
Inclusion Criteria
The participants must meet all the following criteria to be
considered eligible for the study:
• Male or female aged ≥16 years
• Asthma (confirmed by spirometry or airway inflammation
and function tests) with a smoking history of ≤10 pack-years
• COPD (confirmed by spirometry)
• Bronchiectasis (confirmed by computed tomography scan)
• ILD (confirmed by computed tomography scan and
multidisciplinary team or specialist consensus)
• Primary lung cancer (confirmed diagnosis by histology or
radiology) and not yet started significant treatment
• Current pneumonia (confirmed by chest imaging)
• BPD (specialist confirmed) with no other significant
respiratory comorbidity
• Healthy controls (defined as no current clinical diagnosis
of, or receiving treatment for, a lung disorder or other
significant medical disorder)
• Willing and able to give informed consent for participation
in the study
• In a stable state (at least 4 weeks after treatment of an
exacerbation of their respiratory disease)
Exclusion Criteria
The participants may not enter the study if any of the following
apply:
• Existing comorbidities that may prevent them from
performing spirometry (for those with asthma and COPD
or healthy controls) and no spirometry in the previous 12
months (at the discretion of the clinical investigator)
• Unable to comprehend the study, unable to provide
informed consent, and unable to perform any of the study
procedures
• Requirement of supplemental oxygen (participants with
pneumonia only)
Sampling and Sample Size
The sample size was based on the primary objective of
comparing EBC H2O2 values between each of the study groups
(patients with asthma, COPD, ILD, and lung cancer and
controls) based on the results from previous studies (EXHALE
1A and EXHALE 1B), using an older version of the device.
Sample sizes were calculated based on 5% significance and
80% power using a comparison of 2 means (two-tailed t test
across independent groups) and using effect sizes based on the
results of the previous studies.
Using these calculations, we will recruit the following:
• 30 people with COPD
• 35 people with asthma
• 25 people with ILD
• 40 people with lung cancer
• 50 healthy controls
The BPD, bronchiectasis, and pneumonia groups are
exploratory, and no information exists to base their sample size




This is a multicenter study in which the identification of
potential participants are being performed in respiratory
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outpatient clinics, inpatient wards across the hospital, and
integrated specialist community clinics in primary care.
Participants in our research database who have previously
provided their consent to participate in future studies that adhere
to the general data protection regulations will also be offered
the opportunity to participate in this study. People with
suspected lung cancer can be recruited before a confirmed
diagnosis. If tests confirm that the participant does not have
cancer, they can be entered into any other category if
appropriate; otherwise, they will be considered a screen fail.
Healthy volunteers will be recruited from National Health
Service staff, our research database, friends and family of
participants with respiratory disease, and students or staff at the
University of Portsmouth.
Participants will be approached by their clinical care team, and
those who express an interest will be provided with a participant
information sheet (PIS), an opportunity to ask any questions,
and a review with the research team either at that point in time
or at a future convenient date and time.
Pilot Phase
Before starting full recruitment, we will run a pilot phase to
ensure that the device can produce consistent and reliable results.
Participants will be recruited as detailed above, and the study
procedures will be identical. These data will be analyzed as
soon as possible after collection to assess the quality and
accuracy of the results. The criteria for termination of the pilot
phase will be determined by the clinical, engineering, and
manufacturing teams based on the quality of data, safety
information, clinical training, and ease of use.
Study Assessments
Participant Characteristics
Before other study procedures, the characteristics of participants,
which are known to have a potential influence on respiratory
test results, will be documented. These will include the
following:
• Demographics (age, gender, and ethnicity)
• Categories of disease-specific medications that participants
are taking
• Categories of other medical comorbidities
Respiratory Tests
The participants will then perform the EBC H2O2 level
measurement performed by the Inflammacheck device, followed
by spirometry if the participant has asthma or COPD or is a
healthy control, unless this has been done in secondary care or
by the research team within the last 12 months. Following this,
a small subgroup of participants will answer a brief Likert-type
questionnaire regarding their experience. For every
Inflammacheck test, the following will be recorded:
• Whether the test was completed, and if not, the reason for
this
• Any adverse events (AEs) related to the test that are
reported by the participant or noted by the clinical staff
during the test procedures.
Hydrogen Peroxide in Exhaled Breath Condensate
EBC H2O2 will be measured using the Inflammacheck device
according to the manufacturer’s instructions. This involves
simple relaxed tidal breathing for up to 6 minutes into a
disposable mouthpiece attached to the handheld device, while
wearing a nose clip. The Inflammacheck device then provides
a reading of the EBC H2O2. The results will not be recorded in
any clinical notes, as they are not intended to inform patient
management decisions in this study. As this is a point-of-care
test, this investigation can be performed in any clinical
environment. Understandably, preventing cross-contamination
in any era, but especially in this global coronavirus pandemic,
is paramount, and this investigation is performed using a
bacterial viral filter within the mouthpiece, with single-use
disposable valve houses and sensors. The device itself is cleaned
between each participant’s use according to the local cleaning
guidelines for medical devices.
Spirometry
Spirometry (performed conforming to the American Thoracic
Society and European Respiratory Society standards) will only
be performed in patients with asthma and COPD or in healthy
controls who have not undergone spirometry in the last year in
secondary care or by the respiratory research team. Participants
will inhale rapidly and completely from functional residual
capacity, then exhale in an initial forced exhalation, and then
continue exhalation until the end of the breath. FEV1 (measured
in liters), FVC (measured in liters), and FEV1/FVC ratio will
be recorded. FEV1 and FVC will be documented as absolute
values and as a percentage of the predicted value (25). A
minimum of 3 blows will be performed, with 2 blows within
100 milliliters or 5% of each other. Given the current
coronavirus pandemic, spirometry is only being performed if
it will impact clinical decisions.
Self-Completion Questionnaire
A brief self-completion questionnaire will be used in 20
randomly selected participants to evaluate their opinions on the
Inflammacheck device on a Likert-type scale. Participants will
be asked about ease of use, comfort during testing, and
perception and satisfaction of Inflammacheck.
Health Care Professionals’ Self-Completion
Questionnaire
A brief self-completed questionnaire will be used by 5 randomly
selected health care professionals to evaluate their opinions on




Participants who are unable to perform the EBC H2O2
measurement with Inflammacheck or spirometry will not be
withdrawn. The reason for failing to perform these tests will be
documented in the case report form (CRF).
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An AE is any untoward medical occurrence in a participant
taking part in a clinical trial, which does not necessarily have
to have a causal relationship with the device under investigation.
An AE can, therefore, be any unfavorable or unintended sign,
symptom, or disease temporarily associated with the use of the
device, whether or not this has a causal relationship with the
device under investigation.
Recording and Reporting of AEs
There are not expected to be any AEs associated with the use
of the Inflammacheck device, and no AEs were noted during
any of the previous studies that involved this device. Only AEs
that have a reasonable possibility of being attributable to the
device and any other AE considered to be of clinical significance
by the principal investigator (PI; eg, causing harm to the patient)
will be recorded in the CRF and reported to the sponsor as per
their guidelines. We will record all AEs that are observed during
all respiratory test procedures as a study outcome. Any AEs
that do occur and are considered by the PI to be related to the
device will be expedited to the sponsor, research ethics
committee (REC), and the device manufacturer within 7 days.
Lists of the AEs will be provided to the sponsor when requested.
Data Collection and Management
Data collection will be performed by the research team
comprising research doctors, nurses, and clinical research
associates, all of whom have received appropriate training.
Enrollment in the study will be documented in each participant’s
medical notes if they are an inpatient. The data collection forms
are as follows:
• CRF, including participant characteristics and respiratory
test results confirming the underlying diagnosis
• Self-completed questionnaire for participants
The data will be entered into a secure electronic platform.
Anonymized data will be shared electronically with Exhalation
Technology Ltd for analysis and interpretation of the breath
humidity, temperature, breath flow dynamics, and CO2
waveform data. The Inflammacheck results will be uploaded to
a secure shared database to allow analysis and review of the
collected data. Participants will consent to this, and no
identifiable data will be shared.
Data Analysis
All participants with an EBC H2O2 result, as measured by
Inflammacheck, will be analyzed. Subgroup analyses may be
carried out if there are sufficient number of patients with
particular characteristics, such as smokers and nonsmokers.
Analysis of End Points
Summary Statistics
Demographics or baseline characteristics of each study group
will be produced, as well as an overall summary for all groups
combined. Normally distributed continuous variables will be
summarized by the mean and SD, whereas the median and IQR
will be preferred for nonnormally distributed continuous
variables. The number and percentage of subjects in each
category will be recorded for categorical variables.
Primary Analysis
The primary analysis will be a comparison of EBC H2O2 values,
as measured by the Inflammacheck device, between participants
with the index disease and controls and with each other. It is
expected that the EBC H2O2 will have a positively skewed
distribution. To allow for the skewed distribution, one approach
would be to analyze the data on a log-transformed scale and to
compare between groups using analysis of variance, with post
hoc tests performed to compare between pairs of groups. It is
possible that there may be EBC H2O2 measurements below the
lower detection limit, and thus, the previous approach may not
be practical. If measurements are below the detection limit,
nonparametric methods will be used. The Kruskal-Wallis test
will be used to evaluate if differences exist between the 3
groups, with post hoc Mann-Whitney U analyses used to
compare differences between pairs of groups. When comparing
pairs of groups, a Bonferroni correction will be applied to allow
for multiple testing.
Secondary Analyses
The association between the EBC H2O2 measurements and other
parameters (breath temperature, breath humidity, breath flow
dynamics, and CO2 waveforms) will be examined. Associations
between EBC H2O2 and the continuous variables listed above
will be examined using either Pearson or Spearman rank
correlation (as appropriate).
The percentage of attempted tests that failed for each test will
be recorded. The association between patient characteristics
and this outcome will be examined. Assuming that patient
characteristics are categorical in nature, the chi-square test or
Fisher exact test will be used to examine associations with this
outcome. Secondary analyses will be performed for all subjects
combined and for each study group separately.
Exploratory Analysis
The relationship between EBC H2O2 and other lung function
parameters with respiratory disease type will be further
examined, assuming that EBC H2O2 and other factors are
possible predictors of respiratory disease. Respiratory disease
type, using the patient groups included in the study, will be
considered as a binary outcome: healthy versus disease type,
and the analysis will be performed using multivariable logistic
regression. Receiver operator curve characteristic analyses will
also be undertaken to assess the predictability of EBC H2O2
levels to differentiate between healthy volunteers and patients
with respiratory disease. Further analyses will be performed to
assess whether H2O2 alone or in combination with temperature,
humidity, breath flow dynamics, and CO2 waveform
characteristics can discriminate between healthy controls and
those with a lung disorder using sensitivity, specificity, and
receiver operating characteristic curves as well as using
generalized linear models with post hoc least significant
difference testing.
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Procedure for Dealing With Missing, Unused, and Spurious
Data
The analysis will include any measured data values, with
missing values omitted from the analysis. No imputation of the
missing data will be performed. These data will be examined
for outlying values. Where possible, these will be retained in
the data analysis, and their influence will be minimized by a
data transformation or a nonparametric approach. If such
approaches are not practical, the analysis of the primary outcome
will be performed twice, with and without the outlying values.
Ethics
Participant Confidentiality
The study staff will ensure that participants’ anonymity is
maintained. The participants will be identified only by initials
and a participant’s ID number on the CRF and any electronic
database. All documents will be stored securely and will only
be accessible by the study staff and authorized personnel. The
study will comply with the Data Protection Act 2018, which
requires data to be anonymized as soon as it is practicable to
do so.
Other Ethical Considerations
The study was approved by the Berkshire REC (reference
19/SC/0462) in August 2019. They reviewed and approved the
protocol and all study-relevant material. Any changes to the
protocol or relevant study documents will be approved by the
sponsor. If an amendment is made that requires REC approval,
as defined by the REC as a substantial amendment, the changes
will not be instituted until the amendment has been reviewed
and received approval or favorable opinion from the REC and
research and development departments. A protocol amendment
intended to eliminate an apparent immediate hazard to
participants may be implemented immediately, providing that
the REC is notified as soon as possible, and an approval is
requested. Minor amendments as defined by REC as a
nonsubstantial amendment may be implemented immediately,
and the REC will be informed. All participants will have
adequate time to consider participation in the study, as per the
Good Clinical Practice guidelines.
Patients who are already enrolled in other research trials will
be invited and allowed to participate in the study if they wish
to do so. This was discussed with our patient and public
involvement (PPI) representatives who felt that these patients
should have the opportunity to participate in this study and
should not be excluded. There is a possibility that this study
reveals potential new, previously unknown disease pathology.
This would be more likely to occur in healthy controls. If such
a circumstance occurs, then the participant will be told about
the results and immediately referred to the most appropriate
National Health Service department for further review. With
the participant’s consent, a letter will be written to their general
practitioner explaining the findings.
Where possible, this study will be performed alongside an
existing appointment to limit any extra burden to the participant,
and all participants will receive a small compensation for travel
costs. Participants in the pneumonia arm will be recruited while
an inpatient and will not require any additional visits.
Informed Consent
It is the responsibility of the investigator, or a person designated
by the investigator (if acceptable by local regulations), to obtain
written informed consent from each person participating in this
study, after adequate explanation of the aims, methods,
anticipated benefits, and potential hazards of the study using
the PIS.
Electronic consent will be obtained using the REDCap (Research
Electronic Data Capture; Vanderbilt University) platform. Once
participants have read the PIS, they will be asked to enter their
signature (using their cursor or finger if on a tablet device).
Participants will have the opportunity to download or print a
copy of their consent form and the PIS. If a participant is unable
to complete e-consent, they will have the opportunity to sign a
paper consent form when they attend to complete the study visit.
The process for obtaining informed consent will be in
accordance with REC guidance, Good Clinical Practice
guidelines, and any other regulatory requirements that might
be introduced. The PI or delegate and the participant shall both
sign and date the informed consent form before the person can
participate in the study.
The decision regarding participation in the study is entirely
voluntary. The investigator or their nominee shall emphasize
to them that consent regarding study participation may be
withdrawn at any time without penalty or without affecting the
quality or quantity of their future medical care or without loss
of benefits to which the participant is otherwise entitled.
PPI Details
PPI in this study has been sought from patients with firsthand
experience of living with a respiratory disease. Through
face-to-face meetings, email, and telephone contact, we have
discussed the concept, impact, and details of the study with our
patient representatives from local groups. They have contributed
to developing the key questions and setting our study objectives,
ensuring that we answer questions relevant to people with
respiratory diseases. They have helped design the questionnaire
that will be used to record the participant experience of the
device and the PIS.
Results
This study has been receiving funding since 2019 and was
approved by a REC in August 2019. As of May 2020, the pilot
phase has been completed, and 78 participants enrolled into the
VICTORY (Investigation of Inflammacheck to Measure Exhaled
Breath Condensate Hydrogen Peroxide in Respiratory
Conditions) study. The results from this study will be available
in 2022, in anticipation of COVID-19–related delays.
Discussion
An easy-to-use point-of-care device that can be used in any
health care setting and can differentiate between a range of
respiratory conditions would revolutionize the diagnosis of
respiratory conditions. By improving our ability to confirm a
correct diagnosis, we could initiate earlier treatments, reduce
the burden of frequent health care visits, and improve patients’
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quality of life. The Inflammacheck device is noninvasive,
repeatable, and requires minimal participant effort, which are
beneficial attributes for patients with respiratory conditions who
often struggle with breathlessness. The VICTORY study will
evaluate the Inflammacheck device, using EBC H2O2 alongside
further exhaled breath parameters as a diagnostic tool in
respiratory conditions.
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BPD: breathing pattern disorder
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EXHALE 1B: Exhaled Hydrogen Peroxide as a Marker of Lung Disease Study 1–Breathlessness
EXHALE 1V: Exhaled Hydrogen Peroxide as a Marker of Lung Disease Study 1–Validation
FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
H202: hydrogen peroxide
ILD: interstitial lung disease
PI: principal investigator
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PPI: patient and public involvement
REC: research ethics committee
REDCap: Research Electronic Data Capture
ROS: reactive oxygen species
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